Locations:
SearchAdvertisement
Slower drug elimination from the body among females may impact safety and efficacy
Partnerships with local social service agencies key to program success
Study examines modifiable determinants of health disparities
Findings may guide future research and personalized treatments
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Cleveland Clinic Cancer Institute among select group of centers to administer highly personalized treatment
Real-world results reporting aims to make treatments safer and more effective
Ongoing clinical validation in diverse populations refine breast cancer risk substratification
Soft tissue pathologist discusses research into incorporating genomic data to improve risk stratification
Prediction and bioinformatic data could prove valuable for therapeutic interventions targeting this malignancy
Phase 3 trial found no survival differences between weekly or biweekly doxorubicin/cyclophosphamide or between weekly or biweekly paclitaxel
Advertisement
Advertisement